Learnings from COVID-19 vaccine production could improve treatment for rare diseases
25 Jun 2021
Public and private sector collaboration, combined with a focus on gathering real-world evidence, enabled the rapid development of the Pfizer COVID-19 vaccine. Reda Guiha, Regional President for rare diseases at Pfizer, urges the same approach should be taken for treating rare diseases, as access to care is a critical unmet need.
The Parliament Magazine